Loading…
No business profile yet.
Size PROTEINA (468530.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $450M, the 360th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩55,000 on 6 Nov 2026.
Performance Over six months the shares fell 2.5%, against -19.0% for the median peer and -24.5% for the South Korea market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue fell 59.5% over the last twelve months (peer median +2.3%); the operating margin is -1,178.2% (peer median 3.7%).
Valuation It trades at 26.75× book value against a peer median of 2.92× (3rd most expensive of 21).
Price implies The share price implies a return on equity of about 69.0%; PROTEINA delivers -68.1%, so the price asks more than the business earns today.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.44B | ₩2.95B | ₩2.30B | ₩578M | ₩466M |
| Revenue growth | — | +28% | +298% | +24% | — |
| Gross profit | -₩502M | ₩503M | ₩942M | ₩503M | n/a |
| EBITDA | -₩15.6B | -₩10.1B | -₩8.04B | n/a | n/a |
| Net income | -₩12.0B | -₩9.01B | -₩5.73B | -₩22.8B | -₩11.4B |
| Free cash flow | -₩11.9B | -₩9.16B | -₩8.40B | -₩5.96B | -₩4.60B |
| Capital expenditure | ₩1.88B | ₩1.51B | ₩2.38B | ₩327M | ₩1.25B |
| Total debt | ₩728M | ₩867M | ₩1.01B | ₩16.7B | ₩5.70B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 468530.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +25.0% | -8.0% | 2nd highest of 21 |
| 6-month return | -2.5% | -19.0% | 6th highest of 21 |
| Return on equity | -68.1% | 1.8% | 2nd lowest of 20 |
| Price / book | 26.75× | 2.92× | 3rd most expensive of 21 |
| ROE the price implies | 69.0% | 17.0% | 3rd most demanding of 21 |
| ROE delivered | -68.1% | 1.7% | 2nd lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | ROE | Price / book | Implied ROE | Delivered ROE |
|---|---|---|---|---|---|---|---|---|
| PROTEINA 468530.KS | South Korea | $450M | -2% | -59% | -68% | 26.75× | 69.0% | -68.1% |
| Brainsway Ltd Sponsored ADR BWAY | United States | $450M | -35% | +32% | 13% | 5.65× | 52.0% | 12.9% |
| Hunan Sundy Science and Technology 300515.SZ | China | $453M | -13% | +10% | 24% | 2.99× | 19.0% | 23.7% |
| Eiken Chemical 4549.T | Japan | $454M | -29% | +4% | 4% | 1.62× | 9.9% | 4.2% |
| Chison Medical Technologies 688358.SS | China | $443M | -16% | -1% | 8% | 2.19× | 15.7% | 8.4% |
| Guanhao Biotech 300238.SZ | China | $440M | -25% | -7% | 3% | 4.86× | 33.7% | 3.0% |
| Jenscare Scientific 9877.HK | Hong Kong | $463M | -32% | +993% | -18% | 2.85× | 16.7% | -18.3% |
| 908 Devices MASS | United States | $436M | +29% | +1% | -25% | 3.17× | 19.3% | -24.9% |
| Shanghai Titan Scientific 688133.SS | China | $432M | -22% | -5% | -3% | 1.06× | 11.5% | -3.0% |
| Jiangsu Huayang Intelligent Equipment 301502.SZ | China | $470M | +35% | -5% | 2% | 4.59× | 42.6% | 1.6% |
| Guangzhou Jet Bio-Filtration 688026.SS | China | $471M | +40% | +5% | 2% | 2.51× | 22.6% | 2.0% |
| NeuroPace NPCE | United States | $429M | -32% | +12% | -122% | 36.06× | 428.0% | -122.1% |
| Huaren Pharmaceutical 300110.SZ | China | $472M | -16% | -3% | -44% | 3.64× | 17.4% | -44.2% |
| Shoulder Innovations SI | United States | $428M | +56% | +61% | -41% | 3.44× | 14.6% | -40.5% |
| Guangdong Shirongzhaoye 002016.SZ | China | $473M | -28% | -31% | 2% | 0.63× | 4.8% | 1.8% |
| Shanghai Kindly Enterprises Development 603987.SS | China | $474M | -14% | 0% | 8% | 1.12× | 9.7% | 8.4% |
| Shofu 7979.T | Japan | $475M | +27% | +7% | 13% | 1.47× | 7.1% | 13.2% |
| China Isotope & Radiation 1763.HK | Hong Kong | $478M | -38% | -5% | 6% | 0.64× | 6.0% | n/a |
| SS Innovations International SSII | United States | $423M | -45% | +90% | -26% | 7.91× | 29.6% | -26.1% |
| YD Bio YDES | United States | $423M | -58% | +17% | n/a | 94.54× | 320.5% | n/a |
| Beijing Leadman Biochemistry 300289.SZ | China | $483M | -11% | -6% | -2% | 1.98× | 14.3% | -1.6% |